View
Publication Type
Conference Proceedings
UWI Author(s)
Author, Analytic
Chin, Sheray N.
Author Role
n/a
Author Affiliation
n/a
Paper/Section Title
A review of the patterns of docetaxel use for hormone refractory prostate cancer (HRPC) at the Princess Margaret Hospital.
Medium Designator
n/a
Connective Phrase
n/a
Editor/Compiler
n/a
Editor/Compiler Role
n/a
Proceedings Title
ASCO Genitourinary Cancers Symposium.
Date of Meeting
February 2009.
Place of Meeting
Orlando, Florida.
Place of Publication
n/a
Publisher Name
n/a
Date of Publication
2009
Date of Copyright
n/a
Volume ID
n/a
Location in Work
n/a
Extent of Work
n/a
Packaging Method
n/a
Series Editor
n/a
Series Editor Role
n/a
Series Title
n/a
Series Volume ID
n/a
Location/URL
n/a
ISBN
n/a
Notes
n/a
Abstract
Background: Docetaxel is standard of care for the treatment of HRPC, based on two large randomized clinical trials. The aim of this study was to determine if docetaxel use and effectiveness in routine clinical practice was similar to that seen in the TAX 327 randomized phase III clinical trial. Methods: A retrospective chart review was undertaken to assess patterns of docetaxel use for HRPC at our institution for the 2-year period since its approval for the first-line treatment of HRPC in 2005. Results: Eighty-eight patients, median age 71 and baseline PSA 107, received docetaxel in the first line setting. Main reasons for initiating docetaxel were rising PSA (90%) and progressive symptoms (71%). Eighteen percent of patients received docetaxel for rising PSA alone. A median of 7 cycles was administered. PSA response rates were 61%, time to response 1.5 months, and response duration 6.8 months. Disease progression was the most common reason for treatment discontinuation (36%). Main toxicities were fatigue (32%) and neuropathy (22%). Kaplan Meier survival analysis showed median duration of survival was 15.9 months (95% CI 12.420.5) from first drug use. 1-year survival was 0.63 (95% CI 0.520.72). Post-docetaxel, 36 patients received second-line treatment, mostly with mitoxantrone (89%). Second-line response rates were 22%, and median duration of response was 4 months. Conclusions: In routine clinical practice, docetaxel is a well-tolerated regimen for the treatment of HRPC. Response rates and toxicity profiles were comparable to the randomized trials. However, compared with the TAX 327 clinical trial, survival was slightly shorter than expected (15.9 vs. 18.9 months), possibly due to inclusion of patients with poorer performance status and comorbidities, who may be excluded from clinical trials. Second-line response rates were also comparable with previous reports.....
read more